FDCT.OIDFdctech, INC

10-Q/A: FDCTech Files Q1 2026 Restatement Following Accounting Errors

Sentiment:

Quarterly Report Amendment


FDCTech, Inc. has filed an amended Q1 2026 report to correct financial statement errors, including intercompany eliminations and expense misclassifications.

Capital raiseThe company is pursuing a potential public offering in connection with a contemplated listing on a national securities exchange.

Summary

  • Revenue for Q1 2026 reached $15.21 million, a 154.6% increase compared to $5.98 million in Q1 2025.
  • Net income attributable to FDCTech, Inc. stockholders was $6.87 million for the quarter.
  • The filing is a restatement of the original Q1 2026 report due to identified errors in financial reporting.
  • Corrections included a $3,587 reduction in general and administrative expenses and the reclassification of intercompany cash positions.
  • Total assets as of March 31, 2026, were restated to $72.81 million, while total liabilities were restated to $38.92 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development due to the admission of material weaknesses in internal controls and the necessity of a financial restatement, which undermines investor confidence despite the reported revenue growth.

Positives

  • Significant year-over-year revenue growth of 154.6%.
  • Strong gross profit of $11.63 million for the quarter.
  • Improved working capital position of $30.12 million as of March 31, 2026.
  • Successful integration of Alchemy International Ltd. contributing to brokerage segment expansion.

Negatives

  • Identification of material weaknesses in internal control over financial reporting.
  • Necessity to restate previously issued financial statements for Q1 2026.
  • Ongoing litigation with former shareholders of Alchemy Markets Ltd. regarding acquisition payments.
  • Regulatory penalty appeal pending in Malta regarding a 2019 compliance examination.

Risks

  • Material weaknesses in internal controls could lead to future reporting errors.
  • Potential adverse outcomes in ongoing litigation with former shareholders of Alchemy Markets Ltd.
  • Regulatory and compliance risks associated with operating in multiple international jurisdictions.
  • Geopolitical instability in regions where the company maintains offices, such as Israel.
  • Dependence on successful completion of a contemplated public offering and national exchange listing for liquidity.

Future Outlook

The company intends to continue its strategic growth by integrating acquired subsidiaries, developing its financial technology platforms, and pursuing a potential listing on a national securities exchange (NYSE or Nasdaq) to enhance liquidity.

Management Comments

  • Management believes existing cash and anticipated operating cash flows are sufficient to support operations for at least 12 months.
  • The company is actively working to remediate identified material weaknesses in internal controls.

Industry Context

StockSavvy.ai notes that FDCTech is aggressively scaling its global brokerage footprint through M&A, a common strategy in the fragmented fintech sector, though this rapid expansion has clearly outpaced the company's internal control and reporting infrastructure.

Comparison to Industry Standards

  • The company's reliance on multiple international regulatory licenses (FCA, ASIC, MFSA) is standard for global multi-asset brokers.
  • The use of proprietary trading technology (Condor) is a competitive differentiator compared to firms relying solely on white-label solutions.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Internal Control RemediationImplementation of standardized intercompany reconciliation and enhanced review procedures.2026-06-08Intended to address material weaknesses in financial reporting.

Legal Proceedings

  • Asher Alkoby, et al. v. FDCTech (London Circuit Commercial Court) regarding Share Sale Agreement disputes.
  • FDCTech, Inc. v. Intelligenceline.com, et al. (California Superior Court) regarding defamation claims.
  • Alchemy Markets Ltd. v. FIAU (Malta Court of Appeal) regarding administrative penalties.
  • Alchemy Markets Ltd. v. L-Avukat tal-Istat (Malta Constitutional Court) regarding constitutional challenges to FIAU penalties.

Related Party Transactions

  • Significant receivables and payables with entities controlled by Director Gope S. Kundnani.
  • Executive compensation paid to CEO and CFO via independent contractor arrangements.
  • Seller financing obligation of $2 million to Sync Capital Limited.

Stakeholder Impact

  • Shareholders face increased risk due to internal control failures and ongoing litigation.
  • Creditors and counterparties may be affected by the company's complex intercompany arrangements.

Next Steps

  • Remediation of material weaknesses in internal controls.
  • Continued pursuit of a national securities exchange listing.
  • Resolution of ongoing litigation with former shareholders of Alchemy Markets Ltd.
  • Finalization of the transfer of Alchemy Markets (Cayman) Ltd.

Key Dates

DateDescription
2016-01-21Company founded.
2026-03-31Quarterly period end.
2026-05-15Original Q1 2026 10-Q filing date.
2026-06-03Board concluded previous financial statements should not be relied upon.
2026-06-08Amendment No. 1 (10-Q/A) filing date.

Recommendation

sell

The combination of material weaknesses in internal controls, a financial restatement, and ongoing legal disputes creates significant uncertainty that outweighs the reported revenue growth, making the stock high-risk for institutional investors.

Keywords

FDCTech, Fintech, Brokerage, Restatement, OTC, Financial Technology, Alchemy Markets, Condor Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.